Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

被引：264

作者：

Zumla, Alimuddin ^{[1
,2
]}

Rao, Martin ^{[3
,4
]}

Wallis, Robert S. ^{[5
]}

Kaufmann, Stefan H. E. ^{[6
]}

Rustomjee, Roxana ^{[7
]}

Mwaba, Peter ^{[8
,9
]}

Vilaplana, Cris ^{[10
]}

Yeboah-Manu, Dorothy ^{[11
]}

Chakaya, Jeremiah ^{[12
]}

Ippolito, Giuseppe ^{[13
]}

Azhar, Esam ^{[14
,15
]}

Hoelscher, Michael ^{[16
,17
]}

Maeurer, Markus ^{[3
,4
]}

机构：

[1] UCL, Ctr Clin Microbiol, Div Infect & Immun, London, England

[2] UCL Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England

[3] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden

[4] Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden

[5] Aurum Inst, Johannesburg, South Africa

[6] Max Planck Inst Infect Biol, Berlin, Germany

[7] South African Med Res Council, Cape Town, South Africa

[8] Univ Zambia, Univ Teaching Hosp, UCL Med Sch UNZA UCLMS, Res & Training Project, Lusaka, Zambia

[9] Minist Hlth, Lusaka, Zambia

[10] Fdn Inst Invest Ciencies Salut Germans Trias & Pu, CIBER Enfermedades Resp, Edifici Lab Recerca, Unitat TB Expt, Can Ruti Campus, Barcelona, Spain

[11] Univ Ghana, Noguchi Mem Inst Med Res, Dept Bacteriol, Legon, Ghana

[12] Kenya Govt Med Res Ctr, Nairobi, Kenya

[13] Natl Inst Infect Dis, Rome, Italy

[14] King Abdulaziz Univ, Special Infect Agents Unit, King Fahd Med Res Ctr, Jeddah 21413, Saudi Arabia

[15] King Abdulaziz Univ, Fac Appl Med Sci, Med Lab Technol Dept, Jeddah 21413, Saudi Arabia

[16] Univ Munich, Med Ctr, Div Infect Dis & Trop Med, Munich, Germany

[17] DZIF German Ctr Infect Res, Munich, Germany

来源：

LANCET INFECTIOUS DISEASES | 2016年 / 16卷 / 04期

关键词：

COMMUNITY-ACQUIRED PNEUMONIA; COMBINATION ANTIBIOTIC-THERAPY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HISTONE DEACETYLASE INHIBITORS; CONVERTING ENZYME-INHIBITORS; EBOLA-VIRUS INFECTION; STEM-CELL TRANSPLANT; T-CELLS; MYCOBACTERIUM-TUBERCULOSIS; VITAMIN-D;

D O I：

10.1016/S1473-3099(16)00078-5

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Despite extensive global efforts in the fight against killer infectious diseases, they still cause one in four deaths worldwide and are important causes of long-term functional disability arising from tissue damage. The continuing epidemics of tuberculosis, HIV, malaria, and influenza, and the emergence of novel zoonotic pathogens represent major clinical management challenges worldwide. Newer approaches to improving treatment outcomes are needed to reduce the high morbidity and mortality caused by infectious diseases. Recent insights into pathogen-host interactions, pathogenesis, inflammatory pathways, and the host's innate and acquired immune responses are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. Host-directed therapeutic strategies are now becoming viable adjuncts to standard antimicrobial treatment. Host-directed therapies include commonly used drugs for non-communicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional products, and cellular therapy using the patient's own immune or bone marrow mesenchymal stromal cells. We discuss clinically relevant examples of progress in identifying host-directed therapies as adjunct treatment options for bacterial, viral, and parasitic infectious diseases.

引用

页码：E47 / E63

页数：17

共 174 条

[1] Effective Adjunctive Therapy by an Innate Defense Regulatory Peptide in a Preclinical Model of Severe Malaria [J].